Medicare Expands Coverage for BRACAnalysis CDx in Prostate Cancer
Myriad Genetics, a leader in molecular diagnostics and precision medicine, announced that Medicare has expanded coverage for BRACAnalysis CDx® for men with prostate cancer who are eligible or could become eligible for treatment with Lynparza® (olaparib). BRACAnalysis CDx is the only germline test covered for this indication.
To view full press release click here: PRESS RELEASE
If you would like to learn more about BRACAnalysis CDx® or myRisk®, click here.